JAK抑制剂-话题@MedSci

#JAK抑制剂#

11篇内容 | 3169人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2241057, encodeId=e861224105e6c, content=<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a> <a href='/topic/show?id=c288122059aa' target=_blank style='color:#2F92EE;'>#引发痤疮#</a>, objectTitle=J Dermatolog Treat：JAK抑制剂治疗皮肤病引发痤疮风险分析, objectType=article, longId=853921, objectId=51a8853921bd, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240627/1719492639164_2570354.png, objectUrl=/article/show_article.do?id=51a8853921bd, replyNumber=0, likeNumber=11, createdTime=2024-12-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=陕西省, moduleDTOList=[ModuleDTO(moduleId=51a8853921bd, moduleTitle=J Dermatolog Treat：JAK抑制剂治疗皮肤病引发痤疮风险分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=51a8853921bd)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2228375, encodeId=02aa22283e5e8, content=<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a> <a href='/topic/show?id=d6b83e724b' target=_blank style='color:#2F92EE;'>#BTK抑制剂#</a> <a href='/topic/show?id=8d95109e27ef' target=_blank style='color:#2F92EE;'>#系统性红斑狼疮(SLE)#</a>, objectTitle=Arthritis Rheumatol：Upadacitinib和Elsubrutinib单用或联合治疗中至重度系统性红斑狼疮的疗效与安全性, objectType=article, longId=844805, objectId=4a4d8448053e, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240625/1719297072897_92910.jpg, objectUrl=/article/show_article.do?id=4a4d8448053e, replyNumber=0, likeNumber=56, createdTime=2024-09-29, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=4a4d8448053e, moduleTitle=Arthritis Rheumatol：Upadacitinib和Elsubrutinib单用或联合治疗中至重度系统性红斑狼疮的疗效与安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4a4d8448053e)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2224400, encodeId=6e312224400e4, content=<a href='/topic/show?id=ada39e9465a' target=_blank style='color:#2F92EE;'>#阿达木单抗#</a> <a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a> <a href='/topic/show?id=1cac118e8660' target=_blank style='color:#2F92EE;'>#胃肠道穿孔（GIP）#</a>, objectTitle=Arthritis Rheumatol：JAK抑制剂和阿达木单抗治疗类风湿性疾病患者的胃肠道穿孔发生率会有明显差异吗？, objectType=article, longId=842036, objectId=c27984203698, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240731/1722389920924_92910.jpg, objectUrl=/article/show_article.do?id=c27984203698, replyNumber=0, likeNumber=108, createdTime=2024-09-06, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=c27984203698, moduleTitle=Arthritis Rheumatol：JAK抑制剂和阿达木单抗治疗类风湿性疾病患者的胃肠道穿孔发生率会有明显差异吗？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c27984203698)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2224192, encodeId=a4462224192cd, content=<a href='/topic/show?id=2493130e1a1' target=_blank style='color:#2F92EE;'>#NSCLC#</a> <a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a> <a href='/topic/show?id=d5661393317' target=_blank style='color:#2F92EE;'>#PD1#</a>, objectTitle=读书报告 | JAK抑制剂联合PD1抗体治疗NSCLC, objectType=article, longId=841862, objectId=5a91841862f3, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240904/1725446887318_8538692.jpg, objectUrl=/article/show_article.do?id=5a91841862f3, replyNumber=0, likeNumber=66, createdTime=2024-09-05, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=5a91841862f3, moduleTitle=读书报告 | JAK抑制剂联合PD1抗体治疗NSCLC, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5a91841862f3)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2212754, encodeId=c9ea2212e5481, content=<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a> <a href='/topic/show?id=656be170520' target=_blank style='color:#2F92EE;'>#白癜风#</a>, objectTitle=JAK抑制剂在白癜风治疗中的应用进展, objectType=article, longId=832486, objectId=b957832486a2, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240702/1719890410683_1608702.png, objectUrl=/article/show_article.do?id=b957832486a2, replyNumber=0, likeNumber=92, createdTime=2024-07-02, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=b957832486a2, moduleTitle=JAK抑制剂在白癜风治疗中的应用进展, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b957832486a2)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2211237, encodeId=7bdf221123ee1, content=<a href='/topic/show?id=32af9938ec6' target=_blank style='color:#2F92EE;'>#非小细胞肺癌#</a> <a href='/topic/show?id=bf079890912' target=_blank style='color:#2F92EE;'>#霍奇金淋巴瘤#</a> <a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a> <a href='/topic/show?id=70e6139138a' target=_blank style='color:#2F92EE;'>#PD-1抑制剂#</a>, objectTitle=Science：JAK抑制剂能显著增强PD-1抑制剂抗肿瘤效应, objectType=article, longId=831509, objectId=c91483150959, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20240621/2a957673fcc347d184cdb524a45af6f9-DG7fXJ7PpPgE.jpg, objectUrl=/article/show_article.do?id=c91483150959, replyNumber=0, likeNumber=111, createdTime=2024-06-23, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=威斯康星, moduleDTOList=[ModuleDTO(moduleId=c91483150959, moduleTitle=Science：JAK抑制剂能显著增强PD-1抑制剂抗肿瘤效应, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c91483150959)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2209957, encodeId=fc2c220995e49, content=<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a> <a href='/topic/show?id=5516115534f6' target=_blank style='color:#2F92EE;'>#自身免疫性多内分泌腺病综合征1型#</a>, objectTitle=NEJM：JAK抑制剂Ruxolitinib在治疗自身免疫性多内分泌腺病综合征中的有效性, objectType=article, longId=830024, objectId=f0be83002432, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240614/1718358268774_5579292.jpg, objectUrl=/article/show_article.do?id=f0be83002432, replyNumber=0, likeNumber=80, createdTime=2024-06-14, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=f0be83002432, moduleTitle=NEJM：JAK抑制剂Ruxolitinib在治疗自身免疫性多内分泌腺病综合征中的有效性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f0be83002432)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2182253, encodeId=84d121822535a, content=<a href='/topic/show?id=015c5e95173' target=_blank style='color:#2F92EE;'>#斑秃#</a> <a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>, objectTitle=J Cosmet Dermatol：巴瑞替尼治疗中重度难治性斑秃患者的有效性和安全性: 一项开放标签、单中心研究, objectType=article, longId=809804, objectId=29f780980400, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016434455_4754896.png, objectUrl=/article/show_article.do?id=29f780980400, replyNumber=0, likeNumber=119, createdTime=2024-01-17, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=29f780980400, moduleTitle=J Cosmet Dermatol：巴瑞替尼治疗中重度难治性斑秃患者的有效性和安全性: 一项开放标签、单中心研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=29f780980400)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2170202, encodeId=6c7321e02023b, content=<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a> <a href='/topic/show?id=c0826e93471' target=_blank style='color:#2F92EE;'>#特应性皮炎#</a> <a href='/topic/show?id=656be170520' target=_blank style='color:#2F92EE;'>#白癜风#</a>, objectTitle=JAMA Dermatol：揭示JAK抑制剂：炎症性皮肤病中心血管和血栓风险的隐藏真相, objectType=article, longId=801825, objectId=091780182529, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668017382623_4754896.png, objectUrl=/article/show_article.do?id=091780182529, replyNumber=0, likeNumber=125, createdTime=2023-11-22, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=091780182529, moduleTitle=JAMA Dermatol：揭示JAK抑制剂：炎症性皮肤病中心血管和血栓风险的隐藏真相, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=091780182529)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2116819, encodeId=c9012116819ad, content=这个研究对中国有现实意义，因为中国合并<a href='/topic/show?id=3d745346316' target=_blank style='color:#2F92EE;'>#慢性乙型肝炎#</a>的人很多。合并的<a href='/topic/show?id=f9d08524be' target=_blank style='color:#2F92EE;'>#HBV#</a>再激活率为2.0%，这个比例也不小了，值得重视。不过分析发现，<a href='/topic/show?id=820e3228e1b' target=_blank style='color:#2F92EE;'>#利妥昔单抗#</a>(RTX)、<a href='/topic/show?id=60ba9e805ae' target=_blank style='color:#2F92EE;'>#阿巴西普#</a>以及<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>、白介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)抑制剂的<a href='/topic/show?id=fdd01053199b' target=_blank style='color:#2F92EE;'>#HBV再激活率#</a>为9.0%，6.0% ，1.0%，0.0%，0.0%。总体而言，JAK抑制剂是安全的，当然<a href='/topic/show?id=e0d7546812c' target=_blank style='color:#2F92EE;'>#托珠单抗#</a>等更安全, objectTitle=Immun Inflamm Dis：生物制剂或JAK抑制剂治疗类风湿性关节炎后HBsAg -/ HBcAb+患者乙型肝炎再激活的风险, objectType=article, longId=761107, objectId=9106e611071d, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668024114319_4754896.jpeg, objectUrl=/article/show_article.do?id=9106e611071d, replyNumber=0, likeNumber=162, createdTime=2023-02-28, rootId=0, userName=showtest, userId=8f0715, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=9106e611071d, moduleTitle=Immun Inflamm Dis：生物制剂或JAK抑制剂治疗类风湿性关节炎后HBsAg -/ HBcAb+患者乙型肝炎再激活的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9106e611071d)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=1249519, encodeId=e43e1249519a3, content=<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>, objectTitle=JAK 抑制剂 Olumiant 在 RA 中的新长期阳性数据, objectType=article, longId=220347, objectId=48aa22034ed7, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20211114/1636880285989_5295902.png, objectUrl=/article/show_article.do?id=48aa22034ed7, replyNumber=0, likeNumber=102, createdTime=2022-09-17, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=48aa22034ed7, moduleTitle=JAK 抑制剂 Olumiant 在 RA 中的新长期阳性数据, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=48aa22034ed7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1249518, encodeId=f2d11249518b7, content=<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>, objectTitle=何岚：JAK抑制剂带来风湿免疫病的治疗范式转变, objectType=open_course, longId=960, objectId=960, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/202217/1641546330233_5573504.jpg, objectUrl=https://open.medsci.cn/study/7e23f49609e1, replyNumber=0, likeNumber=84, createdTime=2022-09-17, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7e23f49609e1, moduleTitle=何岚：JAK抑制剂带来风湿免疫病的治疗范式转变, moduleType=open_course, hrefUrl=https://open.medsci.cn/study/7e23f49609e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1249517, encodeId=fab2124951e55, content=<a href='/topic/show?id=7face61750b' target=_blank style='color:#2F92EE;'>#类风湿性关节炎#</a>患者使用<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a><a href='/topic/show?id=065b533e7f3' target=_blank style='color:#2F92EE;'>#感染风险#</a>是否会增加？, objectTitle=J Clin Rheumatol：类风湿性关节炎患者使用JAK抑制剂感染风险是否会增加？, objectType=article, longId=724209, objectId=2b6fe24209ff, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/102373157-95011716.1910x1000.jpg, objectUrl=/article/show_article.do?id=2b6fe24209ff, replyNumber=0, likeNumber=140, createdTime=2022-09-17, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2b6fe24209ff, moduleTitle=J Clin Rheumatol：类风湿性关节炎患者使用JAK抑制剂感染风险是否会增加？, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2b6fe24209ff)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1249516, encodeId=91ce124951645, content=<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>联合<a href='/topic/show?id=54e4104e32f5' target=_blank style='color:#2F92EE;'>#紫外光疗#</a>可更有效的治疗<a href='/topic/show?id=656be170520' target=_blank style='color:#2F92EE;'>#白癜风#</a>, objectTitle=J Dermatolog Treat：JAK抑制剂联合紫外光疗可更有效的治疗白癜风, objectType=article, longId=724908, objectId=0f35e24908bc, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220424/1650787423128_5552845.jpg, objectUrl=/article/show_article.do?id=0f35e24908bc, replyNumber=0, likeNumber=160, createdTime=2022-09-17, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f35e24908bc, moduleTitle=J Dermatolog Treat：JAK抑制剂联合紫外光疗可更有效的治疗白癜风, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f35e24908bc)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1247393, encodeId=84d5124e393fd, content=<a href='/topic/show?id=6d00e616523' target=_blank style='color:#2F92EE;'>#类风湿关节炎#</a><a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>, objectTitle=Sci Advs：研究发现了治疗类风湿关节炎的新型药物, objectType=article, longId=737666, objectId=f89ee37666b6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20220904/1662300648015_8252897.jpg, objectUrl=/article/show_article.do?id=f89ee37666b6, replyNumber=0, likeNumber=149, createdTime=2022-09-06, rootId=0, userName=小小医者, userId=f63e4754896, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f89ee37666b6, moduleTitle=Sci Advs：研究发现了治疗类风湿关节炎的新型药物, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f89ee37666b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=898640, encodeId=025e89864092, content=<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>、IL-17单抗、IL-6和TNF单抗、以及传统的治疗药物，形成<a href='/topic/show?id=7face61750b' target=_blank style='color:#2F92EE;'>#类风湿性关节炎#</a>的治疗选择，这几类药物的<a href='/topic/show?id=b1e545e085e' target=_blank style='color:#2F92EE;'>#安全性#</a>均不错，至少较传统的治疗药物安全性要好，就疗效，使用便捷性而言，目前还没有定论，应该是IL-17，JAK可能会优于IL-6和TNF了。但是IL-17与JAK又如何比较？包括短期与长期的作用，可能都得比一比了。, objectTitle=Ann Rheum Dis：乌帕替尼治疗类风湿性关节炎的安全性, objectType=article, longId=203275, objectId=aa6f2032e594, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20201111/1605099566890_1613704.jpg, objectUrl=/article/show_article.do?id=aa6f2032e594, replyNumber=1, likeNumber=326, createdTime=2020-11-12, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa6f2032e594, moduleTitle=Ann Rheum Dis：乌帕替尼治疗类风湿性关节炎的安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa6f2032e594)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=898633, encodeId=c32189863311, content=<a href='/topic/show?id=a7381e7586' target=_blank style='color:#2F92EE;'>#abrocitinib#</a>作为<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>也会成为<a href='/topic/show?id=f12a103e6970' target=_blank style='color:#2F92EE;'>#特异性皮炎#</a>治疗的选择，未来会与单抗，PDE-5抑制剂等形成竞争，使得治疗多样化，医生的选择也会增加, objectTitle=Abrocitinib治疗中重度特应性皮炎的III期研究：已达到主要终点, objectType=article, longId=203284, objectId=ffda20328428, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20201111/1605109462465_5295902.jpeg, objectUrl=/article/show_article.do?id=ffda20328428, replyNumber=0, likeNumber=223, createdTime=2020-11-12, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ffda20328428, moduleTitle=Abrocitinib治疗中重度特应性皮炎的III期研究：已达到主要终点, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ffda20328428)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=896230, encodeId=21918962305b, content=关节炎药物<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a><a href='/topic/show?id=e55a3203bc' target=_blank style='color:#2F92EE;'>#baricitinib#</a>治疗<a href='/topic/show?id=015c5e95173' target=_blank style='color:#2F92EE;'>#斑秃#</a>，肯定是神药！！另外，PD-1类药物用于白发治疗，也肯定极有开发价值！！, objectTitle=关节炎药物JAK抑制剂Baricitinib治疗斑秃：患者获得显著改善, objectType=article, longId=202774, objectId=0f2d202e740f, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/images/20201009/bc106aace6c3443a8ec166aa196fb240.jpg, objectUrl=/article/show_article.do?id=0f2d202e740f, replyNumber=0, likeNumber=254, createdTime=2020-11-02, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f2d202e740f, moduleTitle=关节炎药物JAK抑制剂Baricitinib治疗斑秃：患者获得显著改善, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f2d202e740f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=890523, encodeId=920f89052367, content=<a href='/topic/show?id=273715882c4' target=_blank style='color:#2F92EE;'>#SAPHO综合征#</a>也应该是免疫系统疾病，目前的类风湿类的生物制剂，或靶向制剂都应该有一定的效果，如<a href='/topic/show?id=575b10395981' target=_blank style='color:#2F92EE;'>#TNFi类#</a>，IL-6单抗，<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>，<a href='/topic/show?id=04a196458e' target=_blank style='color:#2F92EE;'>#IL-17单抗#</a>等，都可能有效。但是，哪一类更为有效，仍然有待深入研究与观察了。甚至将来还有必要寻找SAPHO综合征本身更有针对性的靶点, objectTitle=JAMA Dermatol：协和医院李忱发现托法替布能改善SAPHO综合征患者指甲病变和掌跖脓疱病, objectType=article, longId=201804, objectId=ee8a201804a5, topicUrl=null, isHasObj=0, objectCover=, objectUrl=/article/show_article.do?id=ee8a201804a5, replyNumber=0, likeNumber=298, createdTime=2020-10-07, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ee8a201804a5, moduleTitle=JAMA Dermatol：协和医院李忱发现托法替布能改善SAPHO综合征患者指甲病变和掌跖脓疱病, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ee8a201804a5)], followStatus=false, userIsMember=false, type=1, lengthMark=1), GetTopicListResponse(id=888974, encodeId=63a38889e49c, content=<a href='/topic/show?id=35791023eaf' target=_blank style='color:#2F92EE;'>#JAK抑制剂#</a>的<a href='/topic/show?id=6d00e616523' target=_blank style='color:#2F92EE;'>#类风湿关节炎#</a>患者发生严重感染的风险，这是最受关注的，因为JAK抑制剂的靶点特异性不同，主要针对JAK1，2，3的，因此，感染风险理论上可能有一定的差异，但是事实上，差异并不大。, objectTitle=Rheumatology：接受JAK抑制剂的类风湿关节炎患者发生严重感染的风险, objectType=article, longId=201337, objectId=860520133e20, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/517.jpg, objectUrl=/article/show_article.do?id=860520133e20, replyNumber=0, likeNumber=240, createdTime=2020-09-28, rootId=0, userName=lovetcm, userId=7a3710, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=860520133e20, moduleTitle=Rheumatology：接受JAK抑制剂的类风湿关节炎患者发生严重感染的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=860520133e20)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

JAK抑制剂

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#JAK抑制剂# #引发痤疮#

J Dermatolog Treat：JAK抑制剂治疗皮肤病引发痤疮风险分析

2024-12-06发表于陕西省

梅斯管理员 (审核中...)

前往app查看评论内容

#JAK抑制剂# #BTK抑制剂# #系统性红斑狼疮(SLE)#

Arthritis Rheumatol：Upadacitinib和Elsubrutinib单用或联合治疗中至重度系统性红斑狼疮的疗效与安全性

2024-09-29发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#阿达木单抗# #JAK抑制剂# #胃肠道穿孔（GIP）#

Arthritis Rheumatol：JAK抑制剂和阿达木单抗治疗类风湿性疾病患者的胃肠道穿孔发生率会有明显差异吗？

2024-09-06发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#NSCLC# #JAK抑制剂# #PD1#

读书报告 | JAK抑制剂联合PD1抗体治疗NSCLC

2024-09-05发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#JAK抑制剂# #白癜风#

JAK抑制剂在白癜风治疗中的应用进展

2024-07-02发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#非小细胞肺癌# #霍奇金淋巴瘤# #JAK抑制剂# #PD-1抑制剂#

Science：JAK抑制剂能显著增强PD-1抑制剂抗肿瘤效应

2024-06-23发表于威斯康星

梅斯管理员 (审核中...)

前往app查看评论内容

#JAK抑制剂# #自身免疫性多内分泌腺病综合征1型#

NEJM：JAK抑制剂Ruxolitinib在治疗自身免疫性多内分泌腺病综合征中的有效性

2024-06-14发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#斑秃# #JAK抑制剂#

J Cosmet Dermatol：巴瑞替尼治疗中重度难治性斑秃患者的有效性和安全性: 一项开放标签、单中心研究

2024-01-17发表于上海

梅斯管理员 (审核中...)

前往app查看评论内容

#JAK抑制剂# #特应性皮炎# #白癜风#

JAMA Dermatol：揭示JAK抑制剂：炎症性皮肤病中心血管和血栓风险的隐藏真相

2023-11-22发表于上海

showtest (审核中...)